stockrowAlkermes plc (ALKS) vs Kiniksa Pharmaceuticals International, plc (KNSA)
- Alkermes plc ALKS 44.61 −2.79%
- Kiniksa Pharmaceuticals International, plc KNSA 88.50 −7.93%
Alkermes plc and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Alkermes plc and Kiniksa Pharmaceuticals International, plc are of similar size ($7.5B and $6.9B). Alkermes plc has negative trailing earnings, so its P/E is not meaningful; Kiniksa Pharmaceuticals International, plc trades at 62.1×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.2% against 15.3%. Kiniksa Pharmaceuticals International, plc has the higher net margin (11.6% vs −0.02%) and the higher return on invested capital (57.7% vs 1.54%). Across the 19 metrics below, Kiniksa Pharmaceuticals International, plc leads on 13 and Alkermes plc on 6.
Valuation
Profitability
| Metric | ALKS | KNSA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 82.89% | 90.16% | 53.51% |
| Operating margin | 3.66% | 13.79% | 0.00% |
| Net margin | (0.02%) | 11.58% | (2.45%) |
| Free cash flow margin | 13.03% | 20.85% | 0.00% |
| Return on equity | (0.02%) | 17.59% | (0.80%) |
| Return on assets | (0.01%) | 12.92% | (1.67%) |
| Return on invested capital | 1.54% | 57.65% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack